{"prompt": "['Novartis', 'Confidential', 'Page 52', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', 'Discontinuation of the investigational drug (refer to the Discontinuation of study treatment', 'section), if appropriate', 'Hospitalization of the subject if appropriate', 'Causality assessment of the liver event', 'Thorough follow-up of the liver event should include', \"These investigations can include based on Investigator's discretion: serology tests,\", \"imaging and pathology assessments, hepatologist's consultancy; obtaining more detailed\", 'history of symptoms and prior or concurrent diseases, history of concomitant drug use,', 'exclusion of underlying liver disease', 'All follow-up information, and the procedures performed must be recorded as appropriate in', 'the CRF', '10.2.2', 'Renal safety monitoring', 'The following two categories of abnormal renal laboratory values have to be considered during', 'the course of the study:', 'Serum event:', 'Confirmed (after >24 hours) increase in serum creatinine (sCr) of >25% compared to', 'baseline during normal hydration status', 'Urine event:', 'Albumin-creatinine ratio (ACR) 1g/g or >100 mg/mmol.', 'Protein-creatinine ratio (PCR ) 1g/g or >100 mg/mmol.', 'Every renal laboratory trigger or renal event as defined in Table 16-3 - Appendix 3 should be', 'followed up by the investigator or designated personnel at the trial site as summarized', 'in Section 16.', '11', 'Data Collection and Database management', '11.1', 'Data collection', 'Designated Investigator staff will enter the data required by the protocol into the Electronic', 'Case Report Forms using fully validated software that conforms to US CFR 21 Part 11', 'requirements. Investigator site staff will not be given access to the electronic data capture (EDC)', 'system until they have been trained. Automatic validation programs check for data', 'discrepancies in the eCRFs, allow modification and/or verification of the entered data by the', 'Investigator staff. The Investigator/designee is responsible for assuring that the data entered', 'into the eCRF is complete, accurate and that entry and updates are performed in a timely manner.', 'The Investigator must certify that the data entered is complete and accurate.', 'After final database lock, the Investigator will receive copies of the subject data for archiving', 'at the investigational site.', 'All data should be recorded, handled and stored in a way that allows its accurate reporting,', 'interpretation and verification.']['Novartis', 'Confidential', 'Page 53', 'Amended Protocol Version 03 (Clean)', 'Protocol No. CQAW039A2322', '11.2', 'Database management and quality control', 'Novartis personnel will review the data entered by investigational staff for completeness and', 'accuracy. Electronic data queries stating the nature of the problem and requesting clarification', 'will be created for discrepancies and missing values and sent to the investigational site via the', 'EDC system. Designated Investigator site staff are required to respond promptly to queries and', 'to make any necessary changes to the data.', 'Concomitant treatments and prior medications entered into the database will be coded using the', 'WHO Drug Reference List, which employs the Anatomical Therapeutic Chemical classification', 'system. Medical history/current medical conditions and adverse events will be coded using the', 'Medical dictionary for regulatory activities (MedDRA) terminology.', 'Randomization codes and data about all study treatment(s) dispensed to the subject and all', 'dosage changes will be tracked using an Interactive Response Technology (IRT). The system', 'will be supplied by a vendor, who will also manage the database. The data will be sent', 'electronically to Novartis at specific timelines.', 'Each occurrence of a code break via IRT will be reported to the clinical team and monitor. The', 'code break functionality will remain available until study shut down or upon request of Novartis.', 'Laboratory samples will be processed by a central lab and the results will be provided', 'electronically to Novartis.', 'The PROs will be recorded on site by patients on tablet computers and the database from the', 'vendor will be provided electronically to Novartis. The videos of the nasal endoscopies will be', 'provided to the vendor (either by upload to a cloud server or postage of encrypted USB drives)', 'for central reading. Videos will be read by two independent reviewers to assign the nasal polyp', 'score with a third adjudicating reader making the decision on NPS should the original two', 'readers not agree during their assessment.', 'Once all the necessary actions have been completed and the database has been declared to be', 'complete and accurate, it will be locked and the treatment codes will be unblinded and made', 'available for data analysis. Any changes to the database after that time can only be made after', 'written agreement by Novartis development management.', '11.3', 'Site monitoring', \"Before study initiation, at a site initiation visit or at an Investigator's meeting, a Novartis\", 'representative will review the protocol and data capture requirements (i.e. eCRFs) with the', 'Investigators and their staff. During the study, Novartis employs several methods of ensuring', \"protocol and GCP compliance and the quality/integrity of the sites' data. The field monitor will\", 'visit the site to check the completeness of subject records, the accuracy of data capture / data', 'entry, the adherence to the protocol and to Good Clinical Practice, the progress of enrollment,', 'and to ensure that study treatment is being stored, dispensed, and accounted for according to', 'specifications. Key study personnel must be available to assist the field monitor during these']\n\n###\n\n", "completion": "END"}